Actively Recruiting
Study of IMC-P115C in Advanced PRAME-Positive Cancers
Led by Immunocore Ltd · Updated on 2026-02-25
140
Participants Needed
13
Research Sites
251 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Phase 1 First-in-human study of the safety and efficacy of IMC-P115C as a single agent and in combination with standard of care (SOC) agents in participants with advanced PRAME positive cancers. IMC-P115C is a half-life extended (HLE) ImmTAC targeting PRAME.
CONDITIONS
Official Title
Study of IMC-P115C in Advanced PRAME-Positive Cancers
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1
- HLA-A*02:01-positive
- PRAME-positive tumor as confirmed by testing
- Metastatic or unresectable solid tumors
- Have received, are receiving, relapsed from, refractory to, or intolerant of all therapies
- Male and female participants of childbearing potential who are sexually active with a non-sterilized partner must agree to use highly effective birth control methods
You will not qualify if you...
- Symptomatic or untreated central nervous system metastasis
- Bowel obstruction, perforation, or fistula formation within 3 months before planned first dose
- Ongoing ascites or effusion requiring recent drainages
- Significant ongoing toxicity from prior anticancer treatment
- Out-of-range laboratory values
- Clinically significant lung, heart, or autoimmune disease
- Ongoing need for immunosuppressive treatment
- Significant secondary malignancy
- Hypersensitivity to study drug or its components
- Pregnant or lactating
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 13 locations
1
Cancer Research South Australia (CRSA)
Adelaide, Australia, 5000
Actively Recruiting
2
Linear Clinical Research ltd.
Nedlands, Australia, 06009
Actively Recruiting
3
Melanoma Institute Australia
Wollstonecraft, Australia, 2065
Actively Recruiting
4
UNICANCER - Centre Leon-Berard (CLB)
Lyon, France, 69008
Actively Recruiting
5
Centre Hospitalier Universitaire (CHU) de Toulouse-Institut Universitaire du Cancer de Toulouse-Oncopole (IUCT-Oncopole)
Toulouse, France, 31059
Actively Recruiting
6
Institut Gustave Roussy
Villejuif, France, 94805
Actively Recruiting
7
Fondazione IRCCS - Istituto Nazionale dei Tumori
Milan, Italy, 20133
Actively Recruiting
8
Istituto Europeo di Oncologia
Milan, Italy, 20141
Actively Recruiting
9
Istituto Nazionale Tumori IRCCS Fondazione "G. Pascale"
Naples, Italy, 80131
Actively Recruiting
10
Hospital Universitari Vall d Hebron
Barcelona, Spain, 08035
Actively Recruiting
11
Institut Catala d'Oncologia (ICO) - Hospital Duran i Reynals
Barcelona, Spain, 08908
Actively Recruiting
12
Hospital Universitario Ramon y Cajal
Madrid, Spain, 28034
Actively Recruiting
13
START Madrid - Hospital Universitario Fundación Jiménez Díaz
Madrid, Spain, 28040
Actively Recruiting
Research Team
I
Immunocore Medical Information Global
CONTACT
I
Immunocore Medical Information EU
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here